Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout by Cammalleri, Lisa & Malaguarnera, Mariano
Int. J. Med. Sci. 2007, 4 
 
83
International Journal of Medical Sciences 
ISSN 1449-1907 www.medsci.org 2007 4(2):83-93 
© Ivyspring International Publisher. All rights reserved 
Review 
Rasburicase represents a new tool for hyperuricemia in tumor lysis syn-
drome and in gout 
Lisa Cammalleri and Mariano Malaguarnera 
Dept of Senescence, Urological and Neurological Sciences, University of Catania, Catania, Italy  
Correspondence to: Mariano Malaguarnera, A.P., Via Messina 829 – 95125 Catania (Italy). Phone ++39 95 7262008; Fax ++39 95 7262011; 
E-Mail: malaguar@unict.it 
Received: 2007.01.12; Accepted: 2007.03.01; Published: 2007.03.02 
Hyperuricemia is a feature of several pathologies and requires an appropriate and often early treatment, owing 
to the severe consequences that it may cause. A rapid and massive raise of uric acid, during tumor lysis syn-
drome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney. To prevent or 
treat these consequences, a new therapeutic option is represented by rasburicase, a recombinant form of an en-
zyme, urate oxidase. This enzyme converts hypoxanthine and xanthine into allantoin, a more soluble molecule, 
easily cleared by kidney. The several types of urate oxidase have followed each other, with progressive reduc-
tion of adverse reactions. The most important among them are allergenicity and the development of antibodies 
which compromise their effectiveness. Nevertheless, a limit of rasburicase’s use remains its cost, which obliges 
to a judicious choice to prevent TLS in high risk patients with cancer and in case of allergy or impossibility to 
take allopurinol orally both in TLS and in gout. A large body of evidence confirms the efficacy and safety of 
rasburicase, even in comparison to the standard drugs used in the aforementioned pathologies. 
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1.  Introduction 
Uric acid is a weak organic acid (pKa 5.8), poorly 
water-soluble at acidic pH. It derives partly from diet 
and partly from endogenous biosynthesis and it is 
eliminated by enteric (25-35%) and renal (65-75%) 
ways. We define hyperuricemia the uric acid blood 
level over 8 mg/dl (4.76 µmol/l).[1] The impact of 
hyperuricemia is wide felt because it may cause 
pathologic consequences in several organs, such as 
kidney, brain, subcutaneous tissue, joints. Many stud-
ies underline the direct proportionality between se-
rum urate and risk of gout. [2,3] Hyperuricemia, in 
fact, is considered its biochemical hallmark, because 
the precipitation of uric acid is possible when uric acid 
exceeds the limit of solubility (about 4.20 µmol/l at 37º 
C). Gout attack is one of the most painful situations 
suffered by humans, [4] owing to the crystallization of 
uric acid within joints with the consequent intermit-
tent attacks of arthritis.   
The tophaceous gout is the chronic and insidious 
evolution that happens after 10 or more years. It is 
characterized by the deposition of monosodium urate 
(tophi) in soft tissues around joints, in kidney and in 
subcutaneous tissue.   
Kidney is one of the most involved organs in case 
o f h yp erur ic em ia , b ec au s e it  i s  t h e m ain  s it e o f  ur ic  
acid excretion. Its impairment may be of different 
types. Hyperuricemia is a cause of urolithiasis. Calculi 
predominantly composed of uric acid represent 
around 13% of human kidney stones. [5] 
It is possible also an acute urate nephropathy, 
due to a dramatic and rapid increase of uricemia and 
renal handling of uric acid and urate. The crystals pre-
cipitate and obstruct tubules of distal nephrons and 
collecting ducts, where pH is acidic. The result is a 
tubular necrosis and acute renal failure (ARF) because 
of intrarenal obstruction of urinary flow. After the 
disruption of the tubules, crystals start to accumulate 
in the interstice. Crystallization is worsened by vol-
ume depletion (frequent in neoplastic patients owing 
to vomiting, diarrhoea, fever), that compromises 
glomerular filtration and increases urate concentration 
in distal tubule. Also, low urine pH reduces uric acid 
solubility, worsening crystallization. [6] 
The most frequent causes of ARF are the cy-
tostatic therapies in patients with cancer or blastic cri-
sis in acute leukaemia. The consequent massive cellu-
lar lysis exceeds the renal excretory ability. ARF is re-
versible with early treatment. Calculi are rarely de-
scribed in this kind of renal damage.   
The last type of renal damage is “gouty neph-
ropathy”, occurring when hyperuricemia is persistent 
but mild. In the interstice and in some tubules we can 
find precipitated microcrystals, which lead a chronic 
inflammation, evolving to arteriolosclerosis, tu-
bulo-interstitial fibrosis, glomerulosclerosis [7] and so 
to chronic renal failure.   
H e n c e ,  i n  t h i s  p a p e r  w e  r e v i e w  a  d r u g  t h a t  
quickly reduce uric acid levels, especially in emer-Int. J. Med. Sci. 2007, 4 
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gency situations, such as tumor lysis syndrome (TLS), 
and discuss possible options for using this drug also 
in chronic conditions, such as gout. 
2.  Uric acid synthesis 
The starting point of uric acid synthesis is the ri-
bose–5–phosphate, a pentose derived from glycidic 
metabolism, converted to PRPP (phosphoribosyl py-
rophosphate) and then to phosphoribosilamine, that 
will be transformed into inosine monophosphate 
(IMP). From this intermediate compound derive 
adenosine monophosphate (AMP) and guanosine 
monophosphate (GMP), the purinic nucleotides useful 
for DNA and RNA synthesis, and inosine that will be 
degraded into hypoxanthine and xanthine and finally 
into uric acid. 
Hypoxanthine and guanine may enter in a sal-
vage pathway, using hypoxanthine-guanine phospho-
ribosyltranferase (HGPRT), an enzyme that reconverts 
these purines bases into respective nucleotides. (Table 
1)  
In humans and other primates, urate oxidase 
(uricase), a hepatic enzyme, is inactive as a result of a 
non-sense mutation, originating a stop codon. So, only 
animals which possess uricase are able to transform 
uric acid in a more soluble (5 – 10 times more than uric 
acid) and more eliminable molecule: allantoin. A side 
product of this reaction is hydrogen peroxide, toxic for 
kidney, that is converted in H2O and O2 by catalase. A 
hypothesis considers this mutation as a result of phy-
logenetic evolution, because uric acid has antioxidant 
properties, that protect against neurological degenera-
tive diseases, and increases longevity. [8] Yet, the loss 
of this enzyme arises the consequences derived from 
uric acid poor solubility. Mice with gene inactivation 
of urate oxidase have hyperuricemia and renal tubu-
lopathy. [9] 
In the past, this alternative metabolic pathway, 
absent in men, was exploited in order to reduce uric 
acid levels by making a kind of substitutive therapy. 
Standard drugs used to prevent and treat hyperu-
ricemia may be burdened by several effects that re-
duce efficacy and safety.  
This objective has been achieved with the syn-
thesis of uricase. 
3.  Urate oxidase history 
The first molecule of this kind, synthetized in 
1968 and introduced in France since 1975 and in Italy 
since 1984, was a non-recombinant urate oxidase. [10] 
It was a natural uricase, obtained from Aspergillus fla-
vus cultures (Uricozyme TM), used to prevent and treat 
hyperuricemia occurring during chemotherapy. [10] 
Its slow and poor production and its scarce pu-
rity were the main limits of its use.   
Its proteic nature, the poor accurate process of 
purification and the administration of a molecule, ge-
netically absent in humans, made hypersensitivity 
reactions very probable, even in patients without his-
tory of allergy. Immunogenicity and hypersensitivity, 
in fact, were due to the great number of impurities in 
the preparation. 
Immunogenicity might have caused the produc-
tion of antibodies with possible reduction of drug ef-
ficacy. Hypersensitivity presented with rashes, bron-
chospasm, urticaria and angioedema in about 5% of 
patients. Allergic reactions occurred within 1-17 min-
utes after the beginning of the first infusion. [10]   
Since 1996, the molecule currently used, rasburi-
case (FasturtecTM in Europe, ElitekTM in USA) is ob-
tained by recombinant DNA technique. A genetically 
modified strain of Saccharomyces cerevisiae expresses 
urate oxidase cDNA, cloned from a strain of Aspergil-
lus flavus. [23] It allows to obtain urate oxidase more 
rapidly and in a larger quantity. Also, rasburicase is 
purer with higher activity than non-recombinant urate 
oxidase. During the production process the molecule 
and its structure are totally conserved.   
A modification of a reactive cysteine, obtained 
during the purification process of non-recombinant 
urate oxidase, and the higher purity of rasburicase 
may explain the differences between the old and the 
new urate oxidase. [12] 
In fact, the old and the new urate oxidase do not 
significantly differ from a pharmacodynamic point of 
view; the only difference consists in the reduction of 
rasburicase’s adverse effects. Studies have reported 
the presence of antibodies antirasburicase in some pa-
tients [13], whilst others reported no development of 
antibodies after several days of therapy.[14] 
Four monomers (of a molecular mass of 34 kDa 
each) form rasburicase, that is currently classified as 
detoxifying agent for antineoplastic treatment. Its use 
in other hyperuricemic conditions, such as chronic 
gout, is difficult, because rasburicase has a short 
half-life, which requires a daily administration. So, 
PEGylation technique has been proposed to prolong 
half-life and further reduce immunogenicity.   
The PEGylation consists in binding with a cova-
lent link a protein (adenosine-deaminase, asparagi-
nase, interferons, granulocyte colonystimulating factor, 
liposomal doxyrubicin) to poly(ethylene) glycol. It 
permits to obtain molecule with prolonged half-life 
(terminal half-life between 10-20 days) and thus a 
weekly administration. The PEGylated form of ras-
buricase, a bacterial urate oxidase, was used the first 
time in 1988 to treat a nephropathy induced by uric 
acid in a case of non-Hodgking lymphoma. [15] Then 
PEG-uricase was proposed for cases of uncontrolled 
gout or for intolerance or not compliance to standard 
therapy. [16] It was a mammalian, recombinant urate 
oxidase, modified with monomethoxy-PEG.  [9] The 
use of non-modified, recombinant mammalian uricase 
is impossible, because of its immunogenicity and in-
effectiveness in decreasing uric acid levels. [9] Al-
though PEGylation is a process that could reduce hy-
persensitivity reaction, the development of antibodies 
has been reported. Nevertheless, it could resolve 
spontaneously during the treatment. [16] 
So, maintaining the same efficacy of rasburicase, 
the advantages of PEG-uricase may be: lack of anti-
genicity, absence of side effects and a longer duration 
of activity.   Int. J. Med. Sci. 2007, 4 
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4.  Rasburicase pharmacokynetics 
Information about pharmacokinetics derives by 
the use of rasburicase in children and young adults. 
Few data are available in adults and elderly. [17] 
The distribution volume is similar to the physio-
logical blood volume. It is administered once a day, 
being the half-life is 19 hours. Steady state is achieved 
in 2-3 days. Even after 5 days of treatment, a consis-
tent accumulation has not been reported. [13] Interac-
tion studies have been performed in vitro where ras-
buricase does not show interaction with other drugs. 
Association between rasburicase and allopurinol 
should be avoided, because the latter may reduce the 
effect of rasburicase owing to its inhibition of xanthine 
oxidase and consequent reduced uric acid concentra-
tion. [18] 
Studies about metabolism have not been per-
formed but as other protein, rasburicase metabolism 
occurs by peptide hydrolysis, so liver should not be 
involved and the cytochrome P450 is not inducted or 
inhibited; so even hepatic pathologies do not require 
an adjustment of dosage. [10] Its clearance does not 
depend on renal function. 
5.  Rasburicase pharmacodynamics 
It is an enzyme whose action consists in catalyz-
ing the oxidation of uric acid into allantoin, rapidly 
excreted by the kidneys. Allantoin is poorly toxic and 
easy cleared, also in cases of renal impairment. The 
reaction occurs through an intermediate, 5- hydroxy-
isourate, that will be converted into allantoin with a 
non-enzymatic degradation. [19] This reaction releases 
a molecule of hydrogen peroxide, an oxidant product, 
that human anti-oxidant system (catalase) neutralizes 
producing water and oxygen. Subjects with a glucose 
6 phosphate dehydrogenase deficiency are lacking in 
antioxidant systems, so they do not detoxify hydrogen 
peroxide. Rasburicase is contraindicated in these pa-
tients.  
Rasburicase recommended dose is 0.20 
mg/Kg/die diluted in 50 ml of sodium chloride solu-
tion (0.9%), administered intravenously in 30 minutes, 
daily or twice daily for 5-7 days. Hence, a large num-
ber of studies have tested different doses, even lower 
than standard dose and for shorter period than rec-
ommended. [20] A single dose of rasburicase, at low 
dosage, has showed a rapid reduction of hyperurice-
mia. [21-24] Contemporary use of alkalinization, hy-
dration and rasburicase at 0.10 mg/kg for 3-5 days 
maintains the same efficacy. [25] Anyway, we may 
have favourable issues by changing the dose of ras-
buricase, according to the various clinical states, the 
type of malignancy and drugs used. The use of low 
doses of rasburicase may permit to spare the total cost 
on the management of patients and to reduce the risk 
of the development of antibodies.   
6.  Clinical use 
Tumor Lysis Syndrome (TLS) 
Already before 2002, when Food and Drugs Ad-
ministration (FDA) of US has approved the use of 
urate oxidase for the management of paediatric pa-
tients at risk for TLS (Tumor Lysis Syndrome) [26], 
urate oxidase was used for this purpose with good 
efficacy. [13,14,27-30] Currently US FDA does not ap-
prove its use in adult, instead EU FDA has approved it 
in children and adult. [19]   
Tumor lysis syndrome (TLS) is a spontaneous 
condition (present in haematological malignancies and 
other conditions) or, more frequently, occurring in 
consequence of chemotherapy, radiotherapy or im-
munotherapy. [6,19,31] It is characterized by massive 
and rapid cellular lysis with consequent release of in-
tracellular molecules, a condition that raises the risk of 
morbidity and mortality, even in patients potentially 
curable. TLS is defined as the presence of at least 2 of 
the following laboratory data: hyperuricemia, hyper-
kalemia, hyperphosphatemia, and secondary hypo-
calcemia as described by Cairo- Bishop criteria. [1] 
According to these criteria, the levels of these abnor-
malities must draw away 25% from baselines or ex-
ceed the threshold value showed in table 2. (Table 2) 
Hyperuricemia is very common in patients with 
a neoplastic disease and it is already present at the 
diagnosis or it develops within 48-72 hours after the 
treatment.  
The greater is the growth rate of tumor, the 
higher is the content of DNA and consequently of uric 
acid produced. When uric acid exceeds renal capacity 
of elimination, it precipitates into renal tubules. So, a 
vicious circle  creates  because the consequent renal 
functional impairment worsens hyperkaliemia and 
hyperphosphatemia, phosphorus and calcium bind 
themselves and precipitate within kidneys. (Figure 1)   
These metabolic abnormalities are more harmful 
in neoplastic patients, since their general conditions 
are already compromised by cachexia, malnutrition, 
pain. It is an imperative treating or, better, preventing 
TLS, because each metabolic derangement is associ-
ated with remarkable clinical manifestations.   
Hyperuricemia and hyperphosphatemia severely 
worsen renal functionality; hyperkalemia and hypo-
calcemia compromises regular cardiac rhythm causing 
arrhythmias, sometimes mortal, and neuromuscular 
function, with potential tetany, convulsion, cramping. 
[32] Being the clearance of uric acid, potassium, cal-
cium and phosphate mainly renal, kidneys are over-
loaded, until their excretion ability is saturated with 
great difficulties to eliminate electrolytes, toxic sub-
stances and drugs, with consequent risk of accumula-
tion and toxicity. Uric acid can determine the renal 
impairment in different ways: the local and direct ob-
struction and toxicity on tubules and the local and 
systemic inflammation. Other factors may contribute 
to pathogenesis of ARF: the nephrotoxicity of some 
chemotherapeutic, antibiotics, antiviral and antifungal 
drugs [25], kidney obstruction or compression or renal 
vascular thrombosis in solid tumors. (Figure 2) It is 
necessary to underline that rasburicase controls hy-
peruricemia, but it has not direct effect on the other 
metabolic abnormalities, that will be treated with spe-
cific measures. Int. J. Med. Sci. 2007, 4 
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TLS has been reported in association with several 
tumors: haematologic malignancies and bulky solid 
tumours. [32,33-35]   
The efficacy of rasburicase in the prevention and 
treatment of TLS has been studied by several authors 
who have demonstrated its effectiveness, despite its 
extremely high cost. A Pan-European multicentre 
study has weighed the cost-effectiveness ratios of 
preventing and treating TLS with rasburicase, in hae-
matological malignancies, both in children and adults 
with the conclusion that rasburicase remains a useful 
drug clinically effective and in addition with a fa-
vourable economic outcome in the treatment of hype-
ruricemia. In prevention, instead, its cost-effectiveness 
is favourable in children with all type of haematologi-
cal malignancies and in adults with acute lymphoblas-
tic leukaemia and non-Hodgkin lymphoma, but lower 
in acute myeloid leukaemia because of short average 
life expectancy. [36]   
Rasburicase effectiveness and safety should per-
mit us to spare money from the treatment of conse-
quences of cytoreductive treatments and haemodialy-
sis. 
Therefore, this drug is effective and safe, 
[13,18,20,37-39] but because of its cost, its use is justi-
fied only in some groups of patients which are at risk 
for TLS or have TLS and are allergic to allopurinol or 
cannot ingest it orally. The risk-factors can be related 
to the tumour or to the subjects with cancer (Table 3). 
[19,40,41] Patients in who we may consider the use of 
rasburicase, owing to risk of TLS, are those who have 
hyperuricemia, high tumor burden, high growth rate 
of tumor, high sensitivity to chemotherapy and renal 
impairment.  
Standard measures to prevent and treat hyperu-
ricemia include allopurinol and alkalinization, associ-
ated with an aggressive hydration. Rasburicase pre-
sents various features that give it a more favourable 
profile than standard drugs used for TLS. The classic 
approach to TLS fails in prevention of acute renal fail-
ure in over to 25% of patients. [42]   
Gout  
Even though rasburicase is approved for treat-
ment and prophylaxis of acute hyperuricemia in hae-
matological malignancy with a high tumour burden, 
in order to prevent acute renal failure, it has been used 
for other purposes.   
Life style changes (resulting in obesity), a protein 
richer diet, longevity and the use of some drugs (diu-
retics) have caused an increase of some pathologies, 
such as gout. It affects at least 1% of Western popula-
tion. [43]   
Rasburicase may be able to dissolve tophi in 
therapy-resistant tophaceous gout. [44,45]   
Allopurinol is frequently used in cases of tophi, 
frequent attack of arthritis or urolithiasis. [43]   
Rasburicase is a potential alternative especially 
when allopurinol could not be used because of allergy 
or failure. Uricase reduces tophi volume and generates 
allantoin, which is easily excreted by kidneys, even in 
cases of chronic renal damage. [16] The involvement 
of kidney, frequent in tophaceous gout, in fact, makes 
difficult the use of allopurinol, whose excretion is 
mainly renal. Its dosage should be reduced or discon-
tinued with consequent possible rise of uric acid and 
acute arthritic attack.   
PEG-uricase, the long-acting form, seems to bet-
ter control gout that non-pegylated form. The need for 
a daily administration and the increased probability of 
development of hypersensitivity with re-treatment 
make the use of non-modified rasburicase difficult in 
case of gout. [16] 
PEG uricase accelerates potently tophi dissolu-
tion in 3 month, [46] while they remained stable or 
were partially eliminated with standard therapy. A 
trial, in which PEG-uricase was administered subcu-
taneously in patients with severe, refractory gout at 
doses between 4-24 mg in a single dose, has showed a 
reduction of uric acid pool until 21 days. [16] 
Moreover, rasburicase has been effectively em-
ployed in transplanted patients with gout, where al-
lopurinol in association with azathioprine or cyc-
losporine is contraindicated for the risk of leukocyto-
penia. [47,48] 
Azathioprine is converted into mercaptopurine 
that is metabolized by xanthine oxidase into inactive 
compounds, so the concomitant enzyme inhibition by 
allopurinol causes a conspicuous increase of mercap-
topurine bioavailability, myelotoxicity and risk of 
death. The association between allopurinol and im-
munosuppressive drugs, antineoplastic agent 
(6-mercaptopurine), anticoagulant dicumarol, thiazide 
diuretics, aluminium hydroxide, should be avoided or 
reduced doses of antineoplastic or immunosoppres-
sive or other drugs should be used. It implies a major 
risk of unsuccessful control of tumor or transplant re-
jection. 
A patient who requires the coadministration of 
this kind of drugs, risks a major toxicity, with conse-
quent need of alternative drugs.   
Although allopurinol is usually well tolerated, it 
may cause adverse effects that need a discontinuous 
use, in about 20% of patients. [49] Oxipurinol inhibits 
xanthine oxidase too and is an alternative to allopuri-
nol, but an allergy to allopurinol is a contraindication 
to its use, owing to cross-allergies between them. [50] 
Parental administration, risk of development of 
antibodies and the cell transformation in vitro stimu-
lated by hydrogen peroxide [51] are still limits to us-
ing rasburicase. Currently it is employed in clinical 
trial where the selected patients with severe and to-
phaceous gout are intolerant, allergic, or 
not-responsive to standard therapy. 
Future perspectives for gout are new xanthine 
oxidase inhibitors, including febuxostat, a nonpurine 
analogous, whose metabolism is mainly hepatic, and 
that reduces acid uric levels also in patients with renal 
impairment. [52]   
7.  Advantages of rasburicase  
Rasburicase reduces uric acid levels within 4 
hours both in paediatric and adults patients, so a Int. J. Med. Sci. 2007, 4 
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mounting body of evidence confirms its effectiveness, 
tolerability and safety in the prevention and treatment 
of TLS. Table 4 reports some studies that demonstrate 
the efficacy of rasburicase.   
Rasburicase is very efficacious in the reduction of 
the risk of renal damage during chemotherapy; it can 
dissolve uric acid crystals and can improve renal func-
tions, permitting to continue chemotherapy. [54,55] 
The use of rasburicase is a good option, sometimes 
better than use of allopurinol in patients with severe 
acute hyperuricemia. Allopurinol is a structural 
analogous of hypoxanthine, inhibitor of xanthine oxi-
dase, the last enzyme involved in uric acid synthesis 
pathway. It catalyzes the conversion of hypoxanyhine 
into xanthine and this latter into uric acid. During this 
reaction an active metabolite, deriving by enzymatic 
action on allopurinol, oxypurinol, inhibits xanthine 
oxidase and probably it is responsible for some ad-
verse effects. (Table 5) Moreover, oxypurinol has an 
elimination half-life between 18 – 40 hours, depending 
on renal function (whereas 0.67-1.5 for allopurinol) 
and its concentration increases after protracted ad-
ministration. [56,57] So owing to its activity, its long 
elimination half- life and its urine excretion, it requires 
a dosage reduction, in case of renal impairment.   
Allopurinol action is rather slow in reducing uric 
acid concentration, because acts on the new synthesis 
of uric acid, not on pre-existing uric acid. Hence, sev-
eral days are necessary for before uric acid levels to 
decrease. The maximum effect appears within 14 days. 
[58]   
 Pharmacokinetics and pharmacodynamics of 
allopurinol is different according to aging: its renal 
excretion tends to decrease in elderly, [59] so the tol-
erance to its drugs may progressively decline. 
The use of allopurinol may be complicated by the 
development of nephropathy, rarely reported in lit-
erature, [60] due to its mechanism of action that leads 
t o  a n  i n c r e a s e  o f  h y p o x a nthine (more water soluble 
than uric acid) and xanthine (less water soluble than 
uric acid) concentrations and their precipitation in 
tubules. [61] 
The incidence of acute hyperuricemic nephropa-
thy has become rare using rasburicase. [62]   
Adverse effects of allopurinol are skin rashes, 
pruritus, nephropathy, diarrhoea, headache that often 
require the discontinuation of the medication (5% of 
patients). [49] A severe but rare side effect is hyper-
sensitivity reaction with high-grade fever, bone mar-
row involvement, hepatic and renal toxicity, systemic 
vasculitis, exfoliative dermatitis. [63] This syndrome is 
more probable in patients who are retreated with al-
lopurinol, after the discontinuation for skin rashes. [50] 
As explained, allopurinol action is delayed, because it 
acts on uric acid synthesis. In an oncologic emergency 
condition, such as TLS, we need a drug, as rasburicase, 
with rapid onset of action.   
A comparison between rasburicase and oral al-
lopurinol has showed the major efficacy of rasburicase 
in controlling hyperuricemia in children with a reduc-
tion in serum levels within 4 hours after the first dose 
(-86% rasburicase vs -12% allopurinol). [14] 
Moreover, rasburicase has different features that 
give some advantages, in comparison with allopurinol; 
many of these features are showed in table 6. 
[10,13,54,60]  
For these reasons, allopurinol remains an alter-
native when rasburicase is contraindicated (allergic 
reactions, glucose – 6 – phosphate deydrogenase defi-
ciency) or when TLS risk is low. [1]   
Rasburicase is a good option also in comparison 
with hydration and alkalinization, that are the stan-
dard proceedings of TLS management.   
Hydration, that should be started before and 
continued for several days after the end of chemo-
therapy, helps to dilute the excess of substances, to 
excrete them by an adequate urinary filtration rate 
and to prevent acute urate nephropathy, increasing 
intravascular volume. Hyperidration consists in a 
2.5-3 litres/m2/day liquid administration. [41]   
Hydration is a dangerous measure in patients at 
risk of volume overload and pulmonary edema: eld-
erly or subjects with cardiovascular, renal or hepatic 
diseases.  
The use of alkalinization, with infusion of so-
dium bicarbonate, and oral acetazolamide, during 
chemotherapy is justified because it facilitates clear-
ance of uric acid and neutralizes the tendency to low-
ering of pH in patients with vomiting and diarrhoea.   
It increases solubility and renal excretion of uric 
acid and xanthine, maintaining urinary pH between 
7.0 and 7.3. Nevertheless, if pH exceeds 7.5, precipita-
tion of calcium phosphate occurs, with worsening of 
hypocalcemic symptoms. Rasburicase does not require 
alkalinization [26] even though the use of this practice 
remains a doubt. It may increase acid uric clearance, 
but with a major risk of calcium phosphate precipita-
tion [10] and alteration of blood pH.   
Neither patients treated with non recombinant 
urate oxidase nor those treated with rasburicase re-
quire dialysis. [13,54]   
A retrospective comparison study between Al-
lopurinol and UricozymeTM has showed, in fact, that 
UricozymeTM was more effective and rapid in control-
ling hyperuricemia, urea nitrogen and creatinine lev-
els, eliminating need for dialysis. [54]   
Urate oxidase in the prophylaxis and treatment 
of hyperuricemia and TLS reduces metabolic and re-
nal complications and need for dialysis, which is more 
frequent in patients who receive allopurinol than ras-
buricase (16% vs 2.6%). [27] Other studies do not cor-
relate need for dialysis with use of rasburicase. [64,65] 
In Goldman’s trial, among patients treated with ras-
buricase, none required dialysis. [14] Among 100 pa-
tients with non Hodgink lymphoma, treated with 
rasburicase, during the first cycle of chemotherapy, 
none required dialysis and normalization of uric acid 
levels and control of creatinine levels were achieved. 
[66] 
The absence of needing for dialysis is an advance 
in comparison with other regimes that do not use 
rasburicase, whose need is more remarkable. [67] Int. J. Med. Sci. 2007, 4 
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A protective effect of rasburicase on uric acid 
induced-monocytes apoptosis  has been recently 
demonstrated. The percentage of apoptosis decreases 
when cells, uric acid and urate oxidase are incubated 
together. [68]  
8.  Adverse effects of rasburicase 
According to FDA, hypersensitivity is a risk 
during the treatment with rasburicase, but it’s less 
probable with rasburicase than with non-recombinant 
urate oxidase.   
Repeated use of rasburicase increases risk of hy-
persensitivity reactions: skin rashes (1.4%), urticaria, 
bronchospasm (< 1%), dyspnoea, hypoxemia, ana-
phylactic shock (<1%). [18] In these conditions, pa-
tients should be monitored during the treatment and 
the drugs should immediately be discontinued, asso-
ciating an appropriate antiallergic therapy. Caution 
should be used in patients with a history of allergy.   
A re-treatment has the same efficacy but title of 
antibodies antirasburicase (10-20%) could increase, 
even though most of them are not neutralizing. [69] 
Antibodies develop about 1-6 weeks after administra-
tion. Often, the need for a re-treatment is rarer in neo-
plastic relapse, because this condition is more resistant 
to chemotherapy and so at lower risk of TLS devel-
opment. [13]   
Other adverse reactions are in order of decreas-
ing incidence: fever (6.8%), neutropenia with fever 
(4%), respiratory distress (3%), sepsis (3%), neutro-
penia (2%), mucositis (2%), nausea (1.7%), vomiting 
(1.4%), headache (0.9%), diarrhoea (0.9%), and ab-
dominal pain. [54] 
PEG uricase has been associated with the fol-
lowing adverse reactions: a local injection site indura-
tion, precocious (within few hours) or tardive (8-9 
days), the latter associated with generalized urticaria 
and arthralgia. In some patients, the development of a 
relatively low title of antibodies anti-PEG, not 
anti-uricase, was reported after 7 days. They reduced 
plasma uricase activity. [16]   
Rasburicase is contraindicated in patients with 
glucose-6-phosphate dehydrogenase deficiency, be-
cause it may cause haemolytic anemia or methemo-
globinemia. [70] Hydrogen peroxide (H2O2), an oxi-
dant by-product produced in the reaction catalyzed by 
uricase, is not neutralized because of this enzymatic 
lack. [6,10]   
Moreover, rasburicase should be not adminis-
trated in pregnancy. 
9.  Conclusion 
The increasing development of hyperuricemia, 
due to major incidence of cancer and intensive therapy, 
needs effective and safe drugs. Haematological ma-
lignancies and some bulky solid tumors are at high 
risk of developing hyperuricemia.   
The acute nature of TLS requires, in fact, a quick 
approach because this condition severely worsens 
morbidity and mortality. The rapid action of rasburi-
case could permit to substitute some drugs, whose 
action is too gradual.   
We have reviewed literature data reporting that 
rasburicase may be not only a potent and rapid ap-
proach for prevention and treatment of TLS, but also a 
drug useful in controlling hyperuricemia in chronic 
condition, such as gout. When urate-lowering therapy 
with allopurinol in tophaceous gout is contraindicated 
for allergy or intolerance or interactions with other 
drugs or refractory disease the use of rasburicase 
could be considered.   
Rasburicase is a potent drug with potential ad-
vantages, that could be exploited even in pathologies, 
that differs from the classic indication of rasburicase. 
The long-action of PEG-uricase may be used also in 
patients with hyperuricemia deriving from inherited 
metabolic disorders. [9] (Table 7) 
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Tables and Figures 
Table 1 Metabolic pathway of uric acid 
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Table 2 Metabolic unbalances in TLS 
Metabolic unbalances in TLS 
Hyperuricemia ≥ 476 µmol/l (~ 8.0 mg/dl) 
Hyperphosphatemia ≥ 2.1 mmol/l (children) or 
≥ 1.45 mmol/l (adults)   
 
Hyperkalemia ≥ 6.0 mmol/l 
Hypocalcemia ≤ 1.75 mmol/l 
 
Table 3 Patients at high risk of TLS who could benefit by rasburicase 
Tumor factors    Patients factors   Biochemical  factors 
High tumor burden  Hyperleukocytosis    High uric acid levels 
High tumor growth rate  Pre-existing renal impairment  High LDH levels 
High sensitivity to chemotherapy, especially 
during early treatment phase 
Dehydration  High phosphoremia levels 
Advanced stage of tumor  Poly-pharmacology  Low pH of urine 
Kind of tumor (haematological malignancies 
more than solid tumors) 
  High creatinine levels   
Lymphoma infiltration of kidney       
Use of monoclonal antibodies and targeted 
therapies 
 
  
Table 4 Studies on rasburicase 
Authors  Year  Treatment plan  Patients  Effects on uric acid levels  Other effects  Toxicity 
Pui et al.   
(dose-validation 
phase and ac-
crual phase) 
Phase II trial 
[13] 
2001  Rasburicase for 5-7 
days. Effective 
dose founded is 
0.20 mg/kg   
 
131 children, 
adolescent 
and young 
adults with 
leukaemia or 
lymphoma, 
high tumor 
burden, high 
acid uric and 
creatinine 
levels.  
After 4 hours, uric acid 
decreased (from 9.7 to 1 
mg/dl in 65 patients; 
from 4.3 to 0.5 
mg/dl in 66 patients). 
After chemotherapy, 
uricemia remained low.   
After 1 day, 
creatinine 
levels de-
creased and, 
after 6 days, 
returned 
into normal 
range  
Negligible toxicity, only a 
single case of nausea and 
vomiting. The case of 
bronchospasm and hy-
poxemia might be related 
to hypereosinophily, in-
duced by chemotherapy.   
None of the patients 
needed dialysis 
Jeha et al.   
(North Ameri-
can study – a 
compassionate – 
use trial) [18] 
2005  Rasburicase at a 
dose of 0.20 
mg/kg for 1-7 
days. 
71 patients re-
ceived additional 
courses. 
1069 patients 
(682 children 
and 387 
adults) with 
haematologic 
malignancies 
or solid tu-
mours at risk 
of TLS or with 
TLS 
Uric acid levels remained 
low, also after chemo-
therapy, preventing ef-
fectively TLS. The effi-
cacy of rasburicase in the 
treatment has been 
demonstrated in all hy-
peruricemic adults and in 
98.5% of hyperuricemic 
children.  
  The adverse reactions in 
single course were: head-
ache (0.7%), rash (0.4%), 
fever (0.3%), vomiting 
(0.3%). Only some cases of 
haemolityc anemia (4), 
albunimuria (1), allergic 
reaction (1) and dyspnea 
(1), methemoglobinemia 
(2), hypoxia(2), anaphylac-
tic shock (1), rigor (1), con-
vulsion (1), electrolyte ab-
normalities. 
30 patients developed acute 
renal failure, that required 
haemodialysis. It was 
caused by sepsis or com-
plications of chemotherapy, 
only 10 cases by TLS or 
hyperphosphatemia 
Bosly et al. (in-
ternational 
compassion-
ate-use study) 
[53] 
2003  Rasburicase at 0.20 
mg/kg once a day, 
for 1 to 7 days 
219 children 
and adults at 
risk to TLS 
In hyperuricemic pa-
tients, rasburicase low-
ered uric acid levels (in 
adults from 13.1 mg/dl 
to 0.3 mg/dl after treat-
ment; in children from 
11.3 mg/dl to 0.2 mg/dl) 
  5 patients need dialysis. 
Adverse effects were: 
headache (1.8%), fever 
(1.4%), rigors (1.1%), aller-
gic reactions (0.7%) 
Trifilio et al. 
(retrospective 
study) [24] 
2006  Single dose of 
rasburicase at 3 mg 
and allopurinol, 
hydration and 
other supportive 
therapy in 36 pa-
tients; additional 
dose of 1.5 or 3 mg 
in 6 patient with 
not controlled 
hyperuricemia 
43 adults 
patients with 
cancer  
Both in single dose and in 
double dose, rasburicase 
lowered uric acid levels, 
slower than higher dose 
After 24 
hours, 
creatinine 
levels de-
clined in 39 
patients and 
raised in 4 
ones. 
No patients required dialy-
sis. 
Associazione 
Italiana Ema-
2005 Rasburicase  at 
0.15-0.20 mg/dl 
26 paediatric 
patients at 
Highly significant decline 
of uric acid levels within 
Creatinine 
levels nor-
Well tolerated in all pa-
tients Int. J. Med. Sci. 2007, 4 
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tologia Oncolo-
gia Pediatrica 
(AIEOP) Ex-
perience in Bo-
logna [41] 
for 1-11 days  risk for TLS  24 hours in hyperurice-
mic and in 
non-hyperuricemic pa-
tients. These values were 
maintained during the 
course of treatment 
malized 
within 5 
days after 
the start of 
rasburicase 
Table 5 Mechanism of action of allopurinol 
 
Table 6 Main features of allopurinol and rasburicase 
Allopurinol: a preventive uricogenesis agent  Rasburicase: an uricolytic agent 
It competitively inhibits xanthine oxidase, so prevents further uric 
acid synthesis   
It catalyzes the oxidation of already synthetized uric acid into allan-
toin 
It does not directly alter acid uric levels, so its action is slower and 
gradual, within 24 - 48 h and reaches a maximum after 7-10 days 
Its action is faster in controlling uricemia, within 4 h 
It may increase creatinine levels  It may reduce creatinine levels and urea nitrogen, by improving 
renal function   
It increases precursors of uric acid, such as xanthine, less soluble in 
urine than uric acid. It may impair renal function and improve stone 
formation.  
It does not require alkalinization, so calcium phosphate’s stones 
formation is less probable.   
Its formulation is oral since 1966. 
Since 1999 a new intravenous formulation (not yet available in Italy) 
was introduced in USA   
An intravenous formulation is available 
It needs an adjustment of doses if patient has renal impairment, 
because its active metabolite, oxypurinol, is excreted in urine. 
No adjustment of doses is necessary if patient has renal or hepatic 
impairment. In renal failure, allantoin may accumulate, but it is not 
toxic.  
It has drug-drug interaction with very common agents (chlorpropa-
mide, 6-mercaptopurine, azathioprine, dicumarol, cyclosporine, 
thiazide diuretics) 
No drugs interactions are referred   
Table 7 Clinical uses of rasburicase 
 
Use of rasburicase 
Prophylaxis and treatment of TLS   
Allergy to allopurinol 
Intolerance to allopurinol 
Interaction between allopurinol and other 
drugs 
Elderly 
 Tophaceous gout  
 
Renal failure 
Inherited metabolic disorders 
Perspective use in condition with acute and severe hyperuricemia 
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Figure 1 The systemic effects of cellular lysis and the consequent vicious circle that worsens renal functionality 
 
 
 
 
Figure 2 Multifactorial pathogenesis of ARF (Acute Renal Failure) 